Latest Cambium Bio (ASX:CMB) News

Page 3

Page 3 of 3

Cambium Bio Advances Elate Ocular® with FDA Fast Track and A$3M Capital Raise

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Ada Torres

31 Jan 2025